The latest price target for First Wave BioPharma (NASDAQ: FWBI) was reported by HC Wainwright & Co. on January 26, 2023. The analyst firm set a price target for $18.00 expecting FWBI to rise to within 12 months (a possible 226.09% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for First Wave BioPharma (NASDAQ: FWBI) was provided by HC Wainwright & Co., and First Wave BioPharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of First Wave BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for First Wave BioPharma was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.

While ratings are subjective and will change, the latest First Wave BioPharma (FWBI) rating was a reiterated with a price target of $0.00 to $18.00. The current price First Wave BioPharma (FWBI) is trading at is $5.52, which is within the analyst's predicted range.